2) hemITAM types (e.g., Dectin-1): These CLRs activate NF-B through the Syk-CARD9/Bcl10/MALT1 pathway, consequently influencing the overall immune response
This provides a convenient and cost-effective solution for those looking to manage diabetes or lose weight
However, they come with potential downsides
Cureus 13(3):e14104 Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030
Early data suggests Foundayo can deliver significant weight loss, with patients losing an average of around 27 pounds at higher doses
As pharmaceutical companies gain FDA approval for these drugs specifically for obesity, this trend is expected to continue, further separating their use from traditional diabetes care